Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 256

1.

Bone marrow edema in sacroiliitis: detection with dual-energy CT.

Chen M, Herregods N, Jaremko JL, Carron P, Elewaut D, Van den Bosch F, Jans L.

Eur Radiol. 2020 Feb 13. doi: 10.1007/s00330-020-06670-7. [Epub ahead of print]

PMID:
32055947
2.

What makes or breaks a campaign to stop an invading plant pathogen?

Milne AE, Gottwald T, Parnell SR, Alonso Chavez V, van den Bosch F.

PLoS Comput Biol. 2020 Feb 6;16(2):e1007570. doi: 10.1371/journal.pcbi.1007570. eCollection 2020 Feb.

3.

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial.

van der Heijde D, Song IH, Pangan AL, Deodhar A, van den Bosch F, Maksymowych WP, Kim TH, Kishimoto M, Everding A, Sui Y, Wang X, Chu AD, Sieper J.

Lancet. 2019 Dec 7;394(10214):2108-2117. doi: 10.1016/S0140-6736(19)32534-6. Epub 2019 Nov 12.

PMID:
31732180
4.

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W).

Dougados M, Wei JC, Landewé R, Sieper J, Baraliakos X, Van den Bosch F, Maksymowych WP, Ermann J, Walsh JA, Tomita T, Deodhar A, van der Heijde D, Li X, Zhao F, Bertram CC, Gallo G, Carlier H, Gensler LS; COAST-V and COAST-W Study Groups.

Ann Rheum Dis. 2020 Feb;79(2):176-185. doi: 10.1136/annrheumdis-2019-216118. Epub 2019 Nov 4.

5.

Validation of the self-administered comorbidity questionnaire adjusted for spondyloarthritis: results from the ASAS-COMOSPA study.

Stolwijk C, Essers I, van den Bosch F, Dougados M, Etcheto A, van der Heijde D, Landewé R, Molto A, van Tubergen A, Boonen A.

Rheumatology (Oxford). 2019 Oct 26. pii: kez482. doi: 10.1093/rheumatology/kez482. [Epub ahead of print]

PMID:
31665462
6.

Expert consensus: practical algorithms for management of inflammatory bowel disease patients presenting with back pain or peripheral arthropathies.

Varkas G, Ribbens C, Louis E, Van den Bosch F, Lories R, Vermeire S, Elewaut D, De Vos M.

Aliment Pharmacol Ther. 2019 Dec;50(11-12):1204-1213. doi: 10.1111/apt.15519. Epub 2019 Oct 25. Erratum in: Aliment Pharmacol Ther. 2020 Feb;51(4):485.

PMID:
31650573
7.

Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis.

Kiltz U, Landewé RBM, van der Heijde D, Rudwaleit M, Weisman MH, Akkoc N, Boonen A, Brandt J, Carron P, Dougados M, Gossec L, Jongkees M, Machado PM, Marzo-Ortega H, Molto A, Navarro-Compán V, Niederman K, Sampaio-Barros PD, Slobodin G, Van den Bosch FE, van Tubergen A, van Weely S, Wiek D, Braun J.

Ann Rheum Dis. 2020 Feb;79(2):193-201. doi: 10.1136/annrheumdis-2019-216034. Epub 2019 Oct 11.

8.

Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study.

Baraliakos X, Braun J, Deodhar A, Poddubnyy D, Kivitz A, Tahir H, Van den Bosch F, Delicha EM, Talloczy Z, Fierlinger A.

RMD Open. 2019 Sep 3;5(2):e001005. doi: 10.1136/rmdopen-2019-001005. eCollection 2019.

9.

MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group.

Maksymowych WP, Lambert RG, Østergaard M, Pedersen SJ, Machado PM, Weber U, Bennett AN, Braun J, Burgos-Vargas R, de Hooge M, Deodhar AA, Eshed I, Jurik AG, Hermann KA, Landewé RB, Marzo-Ortega H, Navarro-Compán V, Poddubnyy D, Reijnierse M, Rudwaleit M, Sieper J, Van den Bosch FE, van der Heijde D, van der Horst-Bruinsma IE, Wichuk S, Baraliakos X.

Ann Rheum Dis. 2019 Nov;78(11):1550-1558. doi: 10.1136/annrheumdis-2019-215589. Epub 2019 Aug 17.

PMID:
31422357
10.

MRI of the axial skeleton in spondyloarthritis: the many faces of new bone formation.

Laloo F, Herregods N, Jaremko JL, Carron P, Elewaut D, Van den Bosch F, Verstraete K, Jans L.

Insights Imaging. 2019 Jul 24;10(1):67. doi: 10.1186/s13244-019-0752-4. Review.

11.

Low specificity but high sensitivity of inflammatory back pain criteria in rheumatology settings in Europe: confirmation of findings from a German cohort study.

de Hooge M, van Gaalen FA, Renson T, De Craemer AS, van de Sande MG, Ramonda R, Fagerli KM, Jacobsson LTH, van der Heijde D, Elewaut D, Van den Bosch F.

Ann Rheum Dis. 2019 Nov;78(11):1605-1606. doi: 10.1136/annrheumdis-2019-215742. Epub 2019 Jul 13. No abstract available.

PMID:
31302595
12.

Translating surveillance data into incidence estimates.

Bourhis Y, Gottwald T, van den Bosch F.

Philos Trans R Soc Lond B Biol Sci. 2019 Jul 8;374(1776):20180262. doi: 10.1098/rstb.2018.0262.

PMID:
31104599
13.

Quantifying the hidden costs of imperfect detection for early detection surveillance.

Mastin AJ, van den Bosch F, van den Berg F, Parnell SR.

Philos Trans R Soc Lond B Biol Sci. 2019 Jul 8;374(1776):20180261. doi: 10.1098/rstb.2018.0261.

14.

Treatment with golimumab or infliximab reduces health resource utilization and increases work productivity in patients with ankylosing spondylitis in the QUO-VADIS study, a large, prospective real-life cohort.

Claudepierre P, Van den Bosch F, Sarzi-Puttini P, Vastesaeger N, Govoni M, Kachroo S.

Int J Rheum Dis. 2019 Jun;22(6):995-1001. doi: 10.1111/1756-185X.13526. Epub 2019 Apr 15.

PMID:
30989813
15.

Variability in commercial demand for tree saplings affects the probability of introducing exotic forest diseases.

Alonso Chavez V, Gilligan CA, van den Bosch F.

J Appl Ecol. 2019 Jan;56(1):180-189. doi: 10.1111/1365-2664.13242. Epub 2018 Aug 14.

16.

Plant Virus Epidemiology: Applications and Prospects for Mathematical Modeling and Analysis to Improve Understanding and Disease Control.

Jeger MJ, Madden LV, van den Bosch F.

Plant Dis. 2018 May;102(5):837-854. doi: 10.1094/PDIS-04-17-0612-FE. Epub 2018 Mar 30.

PMID:
30673389
17.

RORγt inhibition selectively targets IL-17 producing iNKT and γδ-T cells enriched in Spondyloarthritis patients.

Venken K, Jacques P, Mortier C, Labadia ME, Decruy T, Coudenys J, Hoyt K, Wayne AL, Hughes R, Turner M, Van Gassen S, Martens L, Smith D, Harcken C, Wahle J, Wang CT, Verheugen E, Schryvers N, Varkas G, Cypers H, Wittoek R, Piette Y, Gyselbrecht L, Van Calenbergh S, Van den Bosch F, Saeys Y, Nabozny G, Elewaut D.

Nat Commun. 2019 Jan 2;10(1):9. doi: 10.1038/s41467-018-07911-6.

18.

Sick leave and its predictors in ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study.

Webers C, Ramiro S, Landewé R, van der Heijde D, van den Bosch F, Dougados M, van Tubergen A, Boonen A.

RMD Open. 2018 Nov 27;4(2):e000766. doi: 10.1136/rmdopen-2018-000766. eCollection 2018.

19.

New bone formation in the intervertebral joint space in spondyloarthritis: An MRI study.

Laloo F, Herregods N, Jaremko JL, Carron P, Elewaut D, Van den Bosch F, Verstraete K, Jans L.

Eur J Radiol. 2018 Dec;109:210-217. doi: 10.1016/j.ejrad.2018.11.007. Epub 2018 Nov 6.

PMID:
30527307
20.

Uncovering the heterogeneity of disease impact in axial spondyloarthritis: bivariate trajectories of disease activity and quality of life.

Imkamp M, Lima Passos V, Boonen A, Arends S, Dougados M, Landewé R, Ramiro S, Van den Bosch F, van der Heijde D, Wink FR, Spoorenberg A, van Tubergen A.

RMD Open. 2018 Nov 14;4(2):e000755. doi: 10.1136/rmdopen-2018-000755. eCollection 2018.

21.

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.

Mease P, Coates LC, Helliwell PS, Stanislavchuk M, Rychlewska-Hanczewska A, Dudek A, Abi-Saab W, Tasset C, Meuleners L, Harrison P, Besuyen R, Van der Aa A, Mozaffarian N, Greer JM, Kunder R, Van den Bosch F, Gladman DD.

Lancet. 2018 Dec 1;392(10162):2367-2377. doi: 10.1016/S0140-6736(18)32483-8. Epub 2018 Oct 22.

22.

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.

van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, Van den Bosch F, Sieper J, Tomita T, Landewé R, Zhao F, Krishnan E, Adams DH, Pangallo B, Carlier H; COAST-V study group.

Lancet. 2018 Dec 8;392(10163):2441-2451. doi: 10.1016/S0140-6736(18)31946-9. Epub 2018 Oct 22.

PMID:
30360964
23.

Sampling for disease absence-deriving informed monitoring from epidemic traits.

Bourhis Y, Gottwald TR, Lopez-Ruiz FJ, Patarapuwadol S, van den Bosch F.

J Theor Biol. 2019 Jan 14;461:8-16. doi: 10.1016/j.jtbi.2018.10.038. Epub 2018 Oct 18.

PMID:
30342894
24.

Clinical and quality of life improvements with golimumab or infliximab in a real-life ankylosing spondylitis population: the QUO-VADIS study.

Van den Bosch F, Flipo RM, Braun J, Vastesaeger N, Kachroo S, Govoni M.

Clin Exp Rheumatol. 2019 Mar-Apr;37(2):199-207. Epub 2018 Jul 19.

PMID:
30148434
25.

Response to: 'Use of dual-energy CT to detect and depict bone marrow oedema in rheumatoid arthritis: is it ready to substitute MRI?' by Wu et al.

Jans L, De Kock I, Herregods N, Verstraete KL, Van den Bosch FE, Carron P, Oei EH, Elewaut D, Jacques P.

Ann Rheum Dis. 2019 Sep;78(9):e90. doi: 10.1136/annrheumdis-2018-213960. Epub 2018 Jul 12. No abstract available.

PMID:
30002086
26.

Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.

Burmester GR, Kremer JM, Van den Bosch F, Kivitz A, Bessette L, Li Y, Zhou Y, Othman AA, Pangan AL, Camp HS.

Lancet. 2018 Jun 23;391(10139):2503-2512. doi: 10.1016/S0140-6736(18)31115-2. Epub 2018 Jun 18.

PMID:
29908669
27.

Clinical management of psoriatic arthritis.

Van den Bosch F, Coates L.

Lancet. 2018 Jun 2;391(10136):2285-2294. doi: 10.1016/S0140-6736(18)30949-8. Epub 2018 Jun 1. Review.

PMID:
29893227
28.

Work participation in spondyloarthritis across countries: analysis from the ASAS-COMOSPA study.

Rodrigues Manica S, Sepriano A, Ramiro S, Pimentel Santos F, Putrik P, Nikiphorou E, Norton S, Molto A, Dougados M, van der Heijde D, Landewé RBM, van den Bosch FE, Boonen A.

Ann Rheum Dis. 2018 Sep;77(9):1303-1310. doi: 10.1136/annrheumdis-2018-213464. Epub 2018 Jun 2.

PMID:
29860232
29.

Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis.

Kiltz U, van der Heijde D, Boonen A, Akkoc N, Bautista-Molano W, Burgos-Vargas R, Wei JC, Chiowchanwisawakit P, Dougados M, Duruoz MT, Elzorkany BK, Gaydukova I, Gensler LS, Gilio M, Grazio S, Gu J, Inman RD, Kim TJ, Navarro-Compan V, Marzo-Ortega H, Ozgocmen S, Pimentel Dos Santos F, Schirmer M, Stebbings S, Van den Bosch FE, van Tubergen A, Braun J.

Ann Rheum Dis. 2018 Sep;77(9):1311-1317. doi: 10.1136/annrheumdis-2017-212076. Epub 2018 Jun 1.

30.

High Rate of Drug-Free Remission After Induction Therapy With Golimumab in Early Peripheral Spondyloarthritis.

Carron P, Varkas G, Renson T, Colman R, Elewaut D, Van den Bosch F.

Arthritis Rheumatol. 2018 Nov;70(11):1769-1777. doi: 10.1002/art.40573.

31.

Long-term efficacy and predictors of remission following adalimumab treatment in peripheral spondyloarthritis: 3-year results from ABILITY-2.

Van den Bosch F, Mease PJ, Sieper J, Baeten DL, Xia Y, Chen S, Pangan AL, Song IH.

RMD Open. 2018 Feb 26;4(1):e000566. doi: 10.1136/rmdopen-2017-000566. eCollection 2018.

32.

Dual-energy CT: a new imaging modality for bone marrow oedema in rheumatoid arthritis.

Jans L, De Kock I, Herregods N, Verstraete K, Van den Bosch F, Carron P, Oei EH, Elewaut D, Jacques P.

Ann Rheum Dis. 2018 Jun;77(6):958-960. doi: 10.1136/annrheumdis-2018-213152. Epub 2018 Mar 1. No abstract available.

PMID:
29496720
33.

Stress and sexual reproduction affect the dynamics of the wheat pathogen effector AvrStb6 and strobilurin resistance.

Kema GHJ, Mirzadi Gohari A, Aouini L, Gibriel HAY, Ware SB, van den Bosch F, Manning-Smith R, Alonso-Chavez V, Helps J, Ben M'Barek S, Mehrabi R, Diaz-Trujillo C, Zamani E, Schouten HJ, van der Lee TAJ, Waalwijk C, de Waard MA, de Wit PJGM, Verstappen ECP, Thomma BPHJ, Meijer HJG, Seidl MF.

Nat Genet. 2018 Mar;50(3):375-380. doi: 10.1038/s41588-018-0052-9. Epub 2018 Feb 12.

PMID:
29434356
34.

Using Epidemiological Principles to Explain Fungicide Resistance Management Tactics: Why do Mixtures Outperform Alternations?

Elderfield JAD, Lopez-Ruiz FJ, van den Bosch F, Cunniffe NJ.

Phytopathology. 2018 Jul;108(7):803-817. doi: 10.1094/PHYTO-08-17-0277-R. Epub 2018 May 22.

35.

Effect of mechanical stress on magnetic resonance imaging of the sacroiliac joints: assessment of military recruits by magnetic resonance imaging study.

Varkas G, de Hooge M, Renson T, De Mits S, Carron P, Jacques P, Moris M, Souverijns G, Jans L, Elewaut D, Van den Bosch F.

Rheumatology (Oxford). 2018 Mar 1;57(3):588. doi: 10.1093/rheumatology/kex534. No abstract available.

PMID:
29329434
36.

Considering behaviour to ensure the success of a disease control strategy.

McQuaid CF, Gilligan CA, van den Bosch F.

R Soc Open Sci. 2017 Dec 6;4(12):170721. doi: 10.1098/rsos.170721. eCollection 2017 Dec.

37.

Effect of mechanical stress on magnetic resonance imaging of the sacroiliac joints: assessment of military recruits by magnetic resonance imaging study.

Varkas G, de Hooge M, Renson T, De Mits S, Carron P, Jacques P, Moris M, Souverijns G, Jans L, Elewaut D, Van den Bosch F.

Rheumatology (Oxford). 2018 Mar 1;57(3):508-513. doi: 10.1093/rheumatology/kex491. Erratum in: Rheumatology (Oxford). 2018 Mar 1;57(3):588.

PMID:
29253272
38.

Prevalence of Comorbidities and Risk Factors for Comorbidities in Patients with Spondyloarthritis in Latin America: A Comparative Study with the General Population and Data from the ASAS-COMOSPA Study.

Bautista-Molano W, Landewé R, Burgos-Vargas R, Maldonado-Cocco J, Moltó A, van den Bosch F, Valle-Oñate R, Dougados M, van der Heijde D.

J Rheumatol. 2018 Feb;45(2):206-212. doi: 10.3899/jrheum.170520. Epub 2017 Dec 15.

PMID:
29247152
39.

Inequity in biological DMARD prescription for spondyloarthritis across the globe: results from the ASAS-COMOSPA study.

Nikiphorou E, van der Heijde D, Norton S, Landewé RB, Molto A, Dougados M, Van den Bosch FE, Ramiro S.

Ann Rheum Dis. 2018 Mar;77(3):405-411. doi: 10.1136/annrheumdis-2017-212457. Epub 2017 Dec 8.

PMID:
29222349
40.

Epidemiology: Past, Present, and Future Impacts on Understanding Disease Dynamics and Improving Plant Disease Management-A Summary of Focus Issue Articles.

Ojiambo PS, Yuen J, van den Bosch F, Madden LV.

Phytopathology. 2017 Oct;107(10):1092-1094. doi: 10.1094/PHYTO-07-17-0248-FI. Epub 2017 Sep 18.

41.

Vitamin D status in spondyloarthritis: results of the ASAS-COMOSPA international study.

Fernandes S, Etcheto A, van der Heijde D, Landewé R, van den Bosch F, Dougados M, Moltó A.

Clin Exp Rheumatol. 2018 Mar-Apr;36(2):210-214. Epub 2017 Nov 16.

42.

Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study.

Tahir H, Deodhar A, Genovese M, Takeuchi T, Aelion J, Van den Bosch F, Haemmerle S, Richards HB.

Rheumatol Ther. 2017 Dec;4(2):475-488. doi: 10.1007/s40744-017-0086-y. Epub 2017 Nov 14.

43.

Association of Comorbidities in Spondyloarthritis With Poor Function, Work Disability, and Quality of Life: Results From the Assessment of SpondyloArthritis International Society Comorbidities in Spondyloarthritis Study.

Nikiphorou E, Ramiro S, van der Heijde D, Norton S, Moltó A, Dougados M, van den Bosch F, Landewé R; Assessment of SpondyloArthritis International Society Comorbidities in Spondyloarthritis Study Task Force.

Arthritis Care Res (Hoboken). 2018 Aug;70(8):1257-1262. doi: 10.1002/acr.23468. Epub 2018 Jun 28.

44.

Extending the durability of cultivar resistance by limiting epidemic growth rates.

Carolan K, Helps J, van den Berg F, Bain R, Paveley N, van den Bosch F.

Proc Biol Sci. 2017 Sep 27;284(1863). pii: 20170828. doi: 10.1098/rspb.2017.0828.

45.

A method of determining where to target surveillance efforts in heterogeneous epidemiological systems.

Mastin AJ, van den Bosch F, Gottwald TR, Alonso Chavez V, Parnell SR.

PLoS Comput Biol. 2017 Aug 28;13(8):e1005712. doi: 10.1371/journal.pcbi.1005712. eCollection 2017 Aug.

46.

Spatial dynamics and control of a crop pathogen with mixed-mode transmission.

McQuaid CF, van den Bosch F, Szyniszewska A, Alicai T, Pariyo A, Chikoti PC, Gilligan CA.

PLoS Comput Biol. 2017 Jul 26;13(7):e1005654. doi: 10.1371/journal.pcbi.1005654. eCollection 2017 Jul.

47.

Physiological Traits Determining Yield Tolerance of Wheat to Foliar Diseases.

van den Berg F, Paveley ND, Bingham IJ, van den Bosch F.

Phytopathology. 2017 Dec;107(12):1468-1478. doi: 10.1094/PHYTO-07-16-0283-R. Epub 2017 Oct 10.

PMID:
28730873
48.

Integrating regulatory surveys and citizen science to map outbreaks of forest diseases: acute oak decline in England and Wales.

Brown N, van den Bosch F, Parnell S, Denman S.

Proc Biol Sci. 2017 Jul 26;284(1859). pii: 20170547. doi: 10.1098/rspb.2017.0547.

49.

The basic reproduction number of vector-borne plant virus epidemics.

Van den Bosch F, Jeger MJ.

Virus Res. 2017 Sep 15;241:196-202. doi: 10.1016/j.virusres.2017.06.014. Epub 2017 Jun 20.

50.

Surveillance to Inform Control of Emerging Plant Diseases: An Epidemiological Perspective.

Parnell S, van den Bosch F, Gottwald T, Gilligan CA.

Annu Rev Phytopathol. 2017 Aug 4;55:591-610. doi: 10.1146/annurev-phyto-080516-035334. Epub 2017 Jun 21. Review.

PMID:
28637378

Supplemental Content

Loading ...
Support Center